Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost bought 39,800 shares of the business’s stock in a transaction dated Wednesday, January 27th. The stock was bought at an average cost of $7.85 per share, for a total transaction of $312,430.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $24,091,265.35. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, January 26th, Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock. The shares were acquired at an average cost of $7.83 per share, for a total transaction of $117,450.00.
  • On Monday, January 25th, Phillip Md Et Al Frost acquired 25,200 shares of Opko Health stock. The shares were acquired at an average cost of $7.99 per share, for a total transaction of $201,348.00.
  • On Thursday, January 21st, Phillip Md Et Al Frost acquired 20,000 shares of Opko Health stock. The shares were acquired at an average cost of $7.85 per share, for a total transaction of $157,000.00.
  • On Wednesday, January 20th, Phillip Md Et Al Frost acquired 58,600 shares of Opko Health stock. The shares were acquired at an average cost of $7.55 per share, for a total transaction of $442,430.00.
  • On Tuesday, January 19th, Phillip Md Et Al Frost acquired 23,400 shares of Opko Health stock. The shares were acquired at an average cost of $7.80 per share, for a total transaction of $182,520.00.
  • On Friday, January 15th, Phillip Md Et Al Frost acquired 65,400 shares of Opko Health stock. The shares were acquired at an average cost of $7.87 per share, for a total transaction of $514,698.00.
  • On Thursday, January 14th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $7.93 per share, for a total transaction of $79,300.00.

Several research firms recently commented on OPK. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Friday, December 4th. Vetr raised Opko Health from a “hold” rating to a “strong-buy” rating and set a $13.37 price objective on the stock in a research report on Wednesday, November 11th. TheStreet raised Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, November 12th. Finally, JPMorgan Chase & Co. began coverage on Opko Health in a research report on Friday, October 16th. They set an “overweight” rating and a $14.00 price objective on the stock. Four analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $15.30.

A number of large investors have recently modified their holdings of the stock. Rice Hall James & Associates LLC raised its stake in shares of Opko Health by 74.3% in the fourth quarter. Rice Hall James & Associates LLC now owns 237,543 shares of the company’s stock worth $2,387,000 after buying an additional 101,221 shares during the period. Essex Investment Management Co. LLC raised its stake in shares of Opko Health by 3.2% in the fourth quarter. Essex Investment Management Co. LLC now owns 320,889 shares of the company’s stock worth $3,225,000 after buying an additional 10,000 shares during the period. Jaffetilchin Investment Partners LLC raised its stake in shares of Opko Health by 12.6% in the fourth quarter. Jaffetilchin Investment Partners LLC now owns 411,833 shares of the company’s stock worth $4,139,000 after buying an additional 45,982 shares during the period. Gilman Hill Asset Management LLC raised its stake in shares of Opko Health by 40.2% in the fourth quarter. Gilman Hill Asset Management LLC now owns 44,758 shares of the company’s stock worth $450,000 after buying an additional 12,837 shares during the period. Finally, Boulegeris Investments Inc. raised its stake in shares of Opko Health by 0.6% in the fourth quarter. Boulegeris Investments Inc. now owns 106,935 shares of the company’s stock worth $1,075,000 after buying an additional 650 shares during the period.

Shares of Opko Health Inc. (NYSE:OPK) traded down 2.67% on Thursday, reaching $7.65. The company’s stock had a trading volume of 2,552,334 shares. The stock’s market cap is $4.17 billion. The firm has a 50 day moving average price of $9.30 and a 200-day moving average price of $10.99. Opko Health Inc. has a 12-month low of $7.12 and a 12-month high of $19.20.

OPKO Health, Inc. (NYSE:OPK) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.

12 Month Chart for NYSE:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.